- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03677362
Weight Loss Intervention in Women With PCOS
31. august 2020 oppdatert av: University of Kansas Medical Center
The proposed single arm 6 mo.
trial will assess the impact of weight loss and fat loss due to a multicomponent remotely-delivered lifestyle intervention on ovulation rates and time-to-ovulation in overweight and obese women with anovulatory infertility caused by PCOS.
Studieoversikt
Status
Fullført
Intervensjon / Behandling
Detaljert beskrivelse
Obesity and visceral adiposity are associated with reproductive dysfunction, specifically infertility, problems with ovulation, and decreased rates of conception.
Approximately 31% of reproductive aged women in the U.S. are obese.
Obese women who become pregnant are at increased risk for miscarriage and pregnancy complications.
Infertility treatment using assisted reproductive technologies such as fertility medications, in vitro fertilization or intracytoplasmic sperm injection, is time-intensive, costly, and less effective in obese compared with normal weight women.
However, attempts at weight loss to date have been modest at best and the effectiveness of single component hypocaloric diets are questionable.
A recently conducted large scale preconception weight loss study in the Netherlands randomized 577 obese infertile women to either a lifestyle intervention prior to fertility treatment or prompt fertility treatment.
This study found significantly higher spontaneous pregnancies in the lifestyle intervention group compared to those who promptly received fertility treatment.
Additionally, when post hoc analyses were completed on predetermined subgroups, researchers found women with anovulation had more spontaneous pregnancies compared to ovulatory women in the lifestyle intervention group.
A few major limitations of this study include: 1) modest weight loss of 4.4 kg and only 38% obtained the minimum goal of 5% weight loss; 2) the study included women with a variety of infertility diagnoses; and 3) limited BMI range of 29-40 kg/m2.
More prospective research is necessary to evaluate the effects of weight loss in anovulatory women caused by Polycystic ovarian syndrome (PCOS) as there may be larger benefits in this population such as restoration of ovulation and spontaneous conception.
Additionally, there has been limited research investigating fat loss after a lifestyle intervention and the impact on ovulation.
Fat loss may play a large role as the purported mechanism by which obesity influences ovulation is through insulin resistance and increased ovarian androgen secretion.
Similar to other populations in need of lifestyle interventions, women seeking fertility treatment also have multiple barriers to weight management.
Infertility treatment centers in major metropolitan cities often draw individuals from large geographical areas including rural dwelling individuals.
Our research team has developed an efficacious weight management program that has shown superior weight loss compared to conventional treatment and has successfully been delivered remotely eliminating concerns of access and transportation and may be well suited for this unique population.
However, the acceptability of a remote delivered weight loss intervention, attendance at behavioral sessions, compliance with diet and physical activity (PA) recommendations and self-monitoring (diet, PA, weight), as well as the impact of the magnitude of weight loss on ovulation rates in overweight and obese anovulatory women are unknown, and will be the focus of this study.
Over a 2 mo.
period, 20 overweight or obese women (BMI > 25 -45 kg/m2, age 21-38 yrs.) seeking initial treatment after 12 mos. of unsuccessful conception (~ 40 new women/mo.)
will be recruited to complete a 6 mo.
multicomponent weight loss intervention (WLI).
Participants must be willing to withhold infertility treatment for the length of the 6 mo.
intervention and have the diagnosis of ovulatory dysfunction (anovulation) caused by PCOS as the primary cause of infertility.
In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages.
Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages.
Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo.
intervention.
Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
Studietype
Intervensjonell
Registrering (Faktiske)
12
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Kansas
-
Kansas City, Kansas, Forente stater, 66160
- University of Kansas Medical Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
21 år til 42 år (Voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Hunn
Beskrivelse
Inclusion Criteria:
- Anovulatory infertility caused by Polycystic ovarian syndrome
- Age 21 to 42.
- Body mass index (BMI) > 25 to 45 kg/m2.
- Weight stable (± 4.6 kg) in previous 3 months
- Willing to delay fertility treatment for 6 mos
Exclusion Criteria:
- Unable to participate in moderate-vigorous physical activity (i.e., brisk walking)
- Currently participating in greater than 3, 30-minute bouts of planned PA/week
- Participation in a weight loss or PA program in the previous 6 mos.
- Currently on a weight loss medication (wash out period 2 mos.)
- Any other infertility diagnosis besides ovulatory dysfunction
- Binge eating disorder as assessed by the Binge Eating Scale.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Weight loss intervention
In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages.
Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages.
Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo.
intervention.
Weekly behavioral counseling sessions (45 min) via Skype will be delivered by a professional health educator (HE) to participants in their homes.
|
In the WLI, energy intake will be prescribed at 1200-1500 kcal/d using commercially available portion-controlled entrées, low calorie shakes, fruits/vegetables, and ad-libitum non-caloric beverages.
Participants will be asked to consume a minimum daily total of 2 entrées (~200 to 300 kcal each, saturated fat ≤ 3g), 3 shakes (~100 kcal each), five 1-cup servings of fruits/vegetables, and ad libitum non-caloric beverages.
Additionally, they will be asked to complete 225 min of moderate intensity PA, and self-monitor diet, PA (self-report) and body weight (home scale) across the 6 mo.
intervention.
Weekly behavioral counseling sessions (45 min) via group phone callsSkype will be delivered by a professional health educator (HE) to participants in their homes.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Ovulation
Tidsramme: 6 months
|
Ovulation will be assessed weekly during the 6 mo.
intervention by ovulation monitoring kit and the OvuSense device.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Fertility related quality of life
Tidsramme: Baseline and 6 months
|
The fertility quality of life (FertiQoL) tool (questionnaire)
|
Baseline and 6 months
|
Body composition
Tidsramme: Baseline and 6 months
|
A dual energy x-ray absorptiometry scan will determine percent body fat.
|
Baseline and 6 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Hovedetterforsker: Courtney Marsh, MD, University of Kansas Medical Center
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
10. september 2018
Primær fullføring (Faktiske)
22. februar 2020
Studiet fullført (Faktiske)
22. februar 2020
Datoer for studieregistrering
Først innsendt
13. september 2018
Først innsendt som oppfylte QC-kriteriene
17. september 2018
Først lagt ut (Faktiske)
19. september 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
1. september 2020
Siste oppdatering sendt inn som oppfylte QC-kriteriene
31. august 2020
Sist bekreftet
1. august 2020
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 142744
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Polycystisk ovariesyndrom
-
Italian Sarcoma GroupPharmaMarRekrutteringMykvevssarkom | Leiomyosarcoma of OvaryItalia
-
Assistance Publique - Hôpitaux de ParisRekrutteringIntensivavdelingens syndrom | Pediatrisk postintensiv syndromFrankrike
-
Hospital Universitario GetafeKarolinska Institutet; Medical University of Lodz; Universidad Politecnica... og andre samarbeidspartnereUkjentSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromPolen, Spania, Sverige
-
Shaare Zedek Medical CenterUkjentPremenstruelt syndrom - PMS
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.FullførtTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapierelatert myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært høyrisiko myelodysplastisk syndromForente stater
-
University of NottinghamMedical Research Council; National Institute for Health Research, United...RekrutteringSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromStorbritannia
-
Esra ÖZERKTO Karatay UniversityRekrutteringPremenstruelt syndrom - PMSTyrkia
-
Geriatric Education and Research InstituteSingapore General Hospital; Changi General Hospital; Sengkang General Hospital og andre samarbeidspartnereFullførtSkrøpelig eldre syndrom | Skrøpelighet | Skrøpelighet syndromSingapore
-
Haukeland University HospitalHar ikke rekruttert ennåSkrøpelig eldre syndrom | Skrøpelighet | Aldring | Skrøpelighet syndromNorge
-
Brigham and Women's HospitalAktiv, ikke rekrutterendeSkrøpelig eldre syndrom | Skrøpelighet | Aldring | Skrøpelighet syndromForente stater
Kliniske studier på Weight loss intervention
-
University of ConnecticutNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbeidspartnereRekruttering
-
Walter Reed Army Medical CenterFullførtDiabetes mellitus type 2
-
University of California, San FranciscoTilbaketrukketSykelig fedmeForente stater
-
University of RochesterFullførtOvervekt | OvervektigForente stater
-
University of PennsylvaniaWeight Watchers InternationalFullført
-
The Cleveland ClinicAbdominal Core Health Quality CollaborativeFullførtBrokk, Ventral | Insisjonell brokkForente stater
-
University of RochesterFullførtOvervekt | OvervektigForente stater
-
University of North Carolina, Chapel HillWeight Watchers InternationalFullførtOvervekt og fedmeForente stater
-
University Hospital, GhentFullført